VP Biologics, Therapeutics & Sterile Quality, Merck Sharpe & Dohme
Global Engage is pleased to announce the Biologics and Biosimilars Congress Asia, co-located with Vaccines R&D and Commercialisation Congress Asia will take place in Singapore on the 27th and 28th November 2018. This event will features over 30 expert speakers over two days and is expected to attract over 150 attendees and 20 poster presentations. This conference is part of Global Engage’s successful Drug Discovery series which includes our Precision Medicine, Medicinal Chemistry, and Synthetic Biology congresses.
The biologics theme will feature cutting-edge research on topics such as modern antibody-based therapeutics & engineering, immunotherapy, and protein biotherapeutics. Presentations on technological advancements such as antibody-drug conjugates (ADCs), success in monoclonal antibody (Mab) and antibody-derived therapeutics for chronic diseases will be extensively covered at the meeting. This field continues to show significant growth with an increasing number of clinical achievements across Asia.
The biosimilars theme explores biosimilar projects growth in Asia. The expert speakers share their insights on development strategies, market access, and commercialisation success. This will allow you, the industries leaders and researchers to track progress and changes in the regulatory environment, clinical trials, and biomanufacturing process. Biosimilars are gaining momentum and prominence as the patents of big branded drugs lapse and cost-cutting initiatives in the healthcare sector. Themes explored in some detail as part of a dedicated panel discussion.
This two-day interactive meeting is a unique opportunity for you to keep up to date on research breakthroughs, regulatory movements and preparing for patent cliffs and disputes through a series of stimulating dialogues